DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 194,600 shares, a growth of 28.4% from the November 30th total of 151,500 shares. Based on an average daily volume of 87,500 shares, the days-to-cover ratio is currently 2.2 days.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $5.41 on Friday. The company has a market capitalization of $231.34 million, a PE ratio of -9.66 and a beta of 1.51. The company’s fifty day moving average is $4.80 and its 200-day moving average is $4.02. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.41.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after acquiring an additional 70,070 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in DiaMedica Therapeutics during the 3rd quarter worth approximately $40,000. Blue Trust Inc. bought a new position in DiaMedica Therapeutics in the 3rd quarter valued at $185,000. Finally, Magnolia Capital Advisors LLC acquired a new position in DiaMedica Therapeutics in the second quarter worth $87,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.